1. Interaction between preservatives and a monoclonal antibody in support of multidose formulation development.
- Author
-
Karunaratne SP, Jolliffe MC, Trayton I, Shanmugam RK, Darton NJ, and Weis DD
- Subjects
- Humans, Preservatives, Pharmaceutical, Cresols chemistry, Phenol chemistry, Benzyl Alcohols, Antibodies, Monoclonal chemistry, Anti-Infective Agents chemistry
- Abstract
Multidose formulations have patient-centric advantages over single-dose formats. A major challenge in developing multidose formulations is the prevention of microbial growth that can potentially be introduced during multiple drawings. The incorporation of antimicrobial preservatives (APs) is a common approach to inhibit this microbial growth. Selection of the right preservative while maintaining drug product stability is often challenging. We explored the effects of three APs, 1.1 % (w/v) benzyl alcohol, 0.62 % (w/v) phenol, and 0.42 % (w/v) m-cresol, on a model immunoglobulin G1 monoclonal antibody, termed the "NIST mAb." As measured by hydrogen exchange-mass spectrometry (HX-MS) and differential scanning calorimetry, conformational stability was decreased in the presence of APs. Specifically, flexibility (faster HX) was significantly increased in the C
H 2 domain (HC 238-255) across all APs. The addition of phenol caused the greatest conformational destabilization, followed by m-cresol and benzyl alcohol. Storage stability studies conducted by subvisible particle (SVP) analysis at 40 °C over 4 weeks further revealed an increase in SVPs in the presence of phenol and m-cresol but not in the presence of benzyl alcohol. However, as monitored by size exclusion chromatography, there was neither a significant change in the monomeric content nor an accumulation of soluble aggregate in the presence of APs., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Madeleine C. Jolliffe reports financial support was provided by AstraZeneca PLC. Isabelle Trayton reports financial support was provided by AstraZeneca PLC. Ramesh Kumar Shanmugam reports financial support was provided by AstraZeneca PLC. Nicholas J. Darton reports financial support was provided by AstraZeneca PLC. David Weis reports financial support was provided by Bristol Myers Squibb]., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF